Evidence map›Paper›PMID 30914716›Full record

Trial reportScientific reports2019

Quantifying circulating cell-free DNA in humans.

Romain Meddeb, Zahra Al Amir Dache, Simon Thezenas, Amaëlle Otandault, Rita Tanos, Brice Pastor, Cynthia Sanchez, Joelle Azzi, Geoffroy Tousch, Simon Azan and 5 more

Abstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Romain MeddebIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Zahra Al Amir DacheIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Simon ThezenasIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Amaëlle OtandaultIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Rita TanosIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Brice PastorIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Cynthia SanchezIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Joelle AzziIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Geoffroy TouschIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Simon AzanIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Caroline MolleviIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Antoine AdenisIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Safia El MessaoudiIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Philippe BlacheIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France.
Alain R ThierryIRCM, Institute of Research in Oncology of Montpellier, Montpellier, France. alain.thierry@inserm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To our knowledge, this is the first comprehensive study on the influence of several pre-analytical and demographic parameters that could be a source of variability in the quantification of nuclear and mitochondrial circulating DNA (NcirDNA and McirDNA). We report data from a total of 222 subjects, 104 healthy individuals and 118 metastatic colorectal cancer (mCRC) patients. Approximately 50,000 and 3,000-fold more mitochondrial than nuclear genome copies were found in the plasma of healthy individuals and mCRC patients, respectively. In healthy individuals, NcirDNA concentration was statistically influenced by age (p = 0.009) and gender (p = 0.048). Multivariate analysis with logistic regression specified that age over 47 years-old was predictive to have higher NcirDNA concentration (OR = 2.41; p = 0.033). McirDNA concentration was independent of age and gender in healthy individuals. In mCRC patients, NcirDNA and McirDNA levels were independent of age, gender, delay between food intake and blood collection, and plasma aspect, either with univariate or multivariate analysis. Nonetheless, ad hoc study suggested that menopause and blood collection time might have tendency to influence cirDNA quantification. In addition, high significant statistical differences were found between mCRC patients and healthy individuals for NcirDNA (p < 0.0001), McirDNA (p < 0.0001) and McirDNA/NcirDNA ratio (p < 0.0001). NcirDNA and McirDNA levels do not vary in the same way with regards to cancer vs healthy status, pre-analytical and demographic factors.

Indexed as

AdultCirculating Tumor DNAColorectal NeoplasmsDNA, MitochondrialFemaleHumansMaleMiddle AgedCirculating Tumor DNADNA, Mitochondrial

Identifiers

PMID30914716
PMCPMC6435718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.